scispace - formally typeset
Journal ArticleDOI

Recurrent venous thromboembolism in patients with a partial deficiency of protein S.

Charles T. Esmon
- 13 Dec 1984 - 
- Vol. 311, Iss: 24, pp 1525-1528
Reads0
Chats0
TLDR
The data suggest that the determination of protein S levels will be useful in the evaluation of patients with recurrent thrombosis, and a functional assay for the plasma protein is developed.
Abstract
Protein S is an antithrombotic plasma protein that serves as a cofactor for another plasma protein, activated protein C. Protein S is required for the expression of the anticoagulant effect of activated protein C, which inhibits blood clotting at the levels of factors V and VIII in the blood-clotting cascade. We postulated that patients deficient in protein S would have inadequate regulatory control of the clotting cascade and would be prone to thrombotic disease in a manner similar to that of patients congenitally deficient in protein C. To determine whether protein S deficiency is associated with recurrent thrombosis, we developed a functional assay for the plasma protein. With this assay, the protein S activity of normal persons ranges from 63 to 160 per cent. Using this test, we have now identified six unrelated persons with severe recurrent venous thrombosis who were deficient in protein S, with levels between 15 and 37 per cent while they were not receiving warfarin therapy. Our data sugges...

read more

Citations
More filters
Journal ArticleDOI

Risk factors for venous thromboembolism

TL;DR: Individual risk factors, or combinations thereof, can have important implications for the type and duration of appropriate prophylaxis and should be carefully reviewed to assess the overall risk of VTE in each patient.
Journal ArticleDOI

The molecular basis of blood coagulation

TL;DR: This work focuses on the molecular basis of blood coagulation with particular attention to the biochemistry and regulation of this pathway as it relates to humans in health and disease.
Journal ArticleDOI

Reporting standards in venous disease: An update

TL;DR: Numeric grading schemes for disease severity, risk factors, and outcome criteria present in the original document have been updated to reflect increased knowledge of venous disease and advances in diagnostic techniques.
Journal ArticleDOI

Resistance to activated protein C as a basis for venous thrombosis.

TL;DR: There was a high prevalence of APC resistance among young persons with a history of venous thrombosis, and this resistance appeared to be inherited as an autosomal dominant trait.
References
More filters
Journal ArticleDOI

Deficiency of protein C in congenital thrombotic disease.

TL;DR: It is suggested that the recurrent thrombotic disease in this family is due to an inherited deficiency in protein C, a potent in vitro anticoagulant enzyme and an in vivo profibrinolytic agent.
Journal ArticleDOI

Familial protein s deficiency is associated with recurrent thrombosis

TL;DR: A rapid one-stage clotting assay for protein S to quantitate the level of protein S in their plasma is developed and suggests that protein S deficiency may result in recurrent thrombotic disease.
Journal ArticleDOI

A comparison of human prothrombin, factor IX (Christmas factor), factor X (Stuart factor), and protein S.

TL;DR: Human prothrombin, factor IX, and factor X have been idolated in high yield and characterized as the their amino-terminal sequence, molecular weight, amino acid composition, and migration in sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
Journal ArticleDOI

Regulation of activated protein C by a new protein. A possible function for bovine protein S.

TL;DR: Purified cofactor-protein S caused a large enhancement in the rate of inactivation of Factor Va by activated protein C in the presence of phospholipid, indicating that protein S may be a cofactor foractivated protein C.
Journal ArticleDOI

The inhibition of blood coagulation by activated protein C through the selective inactivation of activated factor V

TL;DR: The results indicated that activated Protein C can inhibit Factor Xa initiated clotting by degrading Factor Va by inhibiting prothrombin activation and protecting Factor Va fromactivated Protein C inactivation by the presence offactor Xa.
Related Papers (5)